We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cytomedix re-brands as Nuo Therapeutics

Cytomedix re-brands as Nuo Therapeutics

October 31, 2014
CenterWatch Staff

Cytomedix, a Gaithersburg, Md.-based pioneer in biodynamic therapies, has launched its new corporate brand identity, Nuo Therapeutics. The company intends to change its corporate name to Nuo Therapeutics, following shareholder approval of the name change proposal at its Annual General Meeting of the company's shareholders on Nov. 12.

The introduction of Nuo Therapeutics and proposed renaming of the company is seen as an important step in the strategic direction initiated by management earlier this year. In the last 10 months, the company has executed a number of transactions aimed at focusing the organization exclusively on the multi-billion dollar U.S chronic wound care market. Major accomplishments include:

  • Out-licensed non-strategic assets
  • Closed its R&D facility
  • Raised $37 million to build and equip a new commercial organization
  • Recruited and retained the initial members of a commercial team
  • Launched the newly branded wound care product Aurix

Dean Tozer, chief commercial officer, said, "With the official launch of Aurix this week, we now are intently focused on growing our revenues within the 17 territories that have been created through recent additions to our direct sales organization. Our intent is to drive demand within both the hospital outpatient wound care centers and Veterans Affairs facilities. We also have expanded our clinical and reimbursement teams with key hires to further support these initiatives. We believe that the market potential for Aurix is substantial, and will seek to maximize this opportunity for the benefit of clinicians, patients, our partners and shareholders."

United States Drug Sponsors

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing